Literature DB >> 19200056

Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.

Sebastiano Sciarretta1, Francesco Paneni, Francesca Palano, Diana Chin, Giuliano Tocci, Speranza Rubattu, Massimo Volpe.   

Abstract

Left ventricular diastolic dysfunction represents a frequent clinical condition and is associated with increased cardiovascular morbidity and mortality. Diastolic dysfunction is the most common cause of HF-PSF (heart failure with preserved ejection fraction). Therefore it becomes important to understand the pathophysiological mechanisms underlying diastolic dysfunction, as well as the effective therapeutic strategies able to antagonize its development and progression. Among the complex pathophysiological factors that may contribute to the development of diastolic dysfunction, the RAAS (renin-angiotensin-aldosterone system) has been shown to play a significant role. Paracrine and autocrine signals of the RAAS promote structural and functional changes in the heart largely linked to increased myocardial fibrosis. Enhanced and dysregulated activity of the RAAS also contributes to the development of volume overload and vasoconstriction with subsequent increases in left ventricular diastolic filling pressures and a higher susceptibility of developing CHF (congestive heart failure). More recently, it has also been suggested that the RAAS may play a role in triggering myocardial and vascular inflammation through the activation of different cell types and the secretion of cytokines and chemokines. RAAS-induced myocardial inflammation leads to perivascular myocardial fibrosis and to the development or progression of diastolic dysfunction. For these reasons pharmacological blockade of the RAAS has been proposed as a rational approach for the treatment of diastolic dysfunction. In fact, ACEIs (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers) and AAs (aldosterone antagonists) have been demonstrated to delay the development and progression from pre-clinical diastolic dysfunction towards CHF, as well as to reduce the morbidity and mortality associated with this condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200056     DOI: 10.1042/CS20080390

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  42 in total

Review 1.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Catechin ameliorates cardiac dysfunction in rats with chronic heart failure by regulating the balance between Th17 and Treg cells.

Authors:  Qi Zhang; Li-Qun Hu; Chang-Sen Yin; Ping Chen; Hong-Qi Li; Xin Sun; Guang Yan
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

3.  Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat.

Authors:  Lixin Ma; Rukhsana Gul; Javad Habibi; Ming Yang; Lakshmi Pulakat; Adam Whaley-Connell; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

4.  Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy.

Authors:  Sandra B Haudek; Jizhong Cheng; Jie Du; Yanlin Wang; Jesus Hermosillo-Rodriguez; JoAnn Trial; George E Taffet; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-05-19       Impact factor: 5.000

Review 5.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

Review 6.  Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade.

Authors:  Massimo Volpe; Francesco Cosentino; Giuliano Tocci; Francesca Palano; Francesco Paneni
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

7.  Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.

Authors:  Brian Bostick; Javad Habibi; Vincent G DeMarco; Guanghong Jia; Timothy L Domeier; Michelle D Lambert; Annayya R Aroor; Ravi Nistala; Shawn B Bender; Mona Garro; Melvin R Hayden; Lixin Ma; Camila Manrique; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

Review 8.  Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction.

Authors:  Guanghong Jia; Yan Jia; James R Sowers
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-29       Impact factor: 5.187

9.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Authors:  Que Liu; Lisa Adams; Anatoly Broyde; Rayne Fernandez; Alain D Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-08-03       Impact factor: 9.951

10.  TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis.

Authors:  Clemens Duerrschmid; Jeffrey R Crawford; Erin Reineke; George E Taffet; Joann Trial; Mark L Entman; Sandra B Haudek
Journal:  J Mol Cell Cardiol       Date:  2013-01-18       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.